Redeye saw a report that was roughly in line with our expectations.
DT posted Q2 net sales in line with our expectations, while adj.
Q2 NII came in 2% above our estimate at DKK 86m while NCI came in at DKK 19m versus our estimate at ...
CapMan's net sales in Q2 amounted to EUR 16.5m, below our estimates and below consensus (EUR 18.
CapMan reported Q2 EBIT of 4.2m, clearly below Refinitiv consensus at EUR 10.
Redeye updates on Xspray Pharma following its Q2 2023 report.
Redeye updates on Better Collective ahead of its Q2-results (due 22 August after market close) where...
Waystream redovisade minskad omsättning och resultat under Q2.
Redeye comments on the outcome of Nitro Games’ rights issue, which was subscribed to 60%, bringing c...
On 1 August, Relais announced the acquisition of NDS Group's Norwegian workshop equipment unit, whic...
Redeye gives its view on the financing commitments of up to USD20m with Negma Group.
• Solid growth, but high costs still hurting margins • More benefits from savings program in Q3e • 1...
Omsättningen ökade på årsbasis men kassaflödet var svagt.
Kvartalet tyngs av minskad efterfrågan inom Supply Chain Solutions.
Redeye comments on Spago Nanomedical’s Q2 2023 report.
Redeye states that Nepa’s preliminary Q2 numbers were roughly in line with Redeye’s estimates, with ...
Redeye is encouraged by the news that Ireland is the first market to receive national approval for M...
Rapporten bekräftar vår syn Rapporten för det andra kvartalet var odramatisk och siffrorna kom in i ...
DT reports its Q2 results on Thursday, July 3rd. We expect the medical business to bring strong reve...
• Market is stabilising, yet uncertain • We lower our short- to medium-term assumptions • New perman...
